Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Short-term Investments (2016 - 2017)

Crescent Biopharma (CBIO) has disclosed Short-term Investments for 3 consecutive years, with $10649.0 as the latest value for Q4 2016.

  • On a quarterly basis, Short-term Investments rose 14.88% to $10649.0 in Q4 2016 year-over-year; TTM through Dec 2016 was $10649.0, a 14.88% increase, with the full-year FY2016 number at $10649.0, up 14.88% from a year prior.
  • Short-term Investments was $10649.0 for Q4 2016 at Crescent Biopharma, up from $9270.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $16293.0 in Q4 2014 to a low of $9270.0 in Q4 2015.
  • A 3-year average of $12536.2 and a median of $12291.0 in 2015 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 43.1% in 2015, then increased 14.88% in 2016.
  • Crescent Biopharma's Short-term Investments stood at $16293.0 in 2014, then crashed by 43.1% to $9270.0 in 2015, then increased by 14.88% to $10649.0 in 2016.
  • Per Business Quant, the three most recent readings for CBIO's Short-term Investments are $10649.0 (Q4 2016), $9270.0 (Q4 2015), and $13933.0 (Q1 2015).